United States Patent 5,767,082: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 5,767,082, titled "Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists," is a significant patent in the field of pharmaceuticals, particularly in the area of reproductive health. This patent, issued to researchers and inventors in the field of peptide chemistry, outlines novel compounds and their applications. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Invention Overview
The patent describes nonapeptide and decapeptide analogs of Luteinizing Hormone-Releasing Hormone (LHRH) that act as antagonists. LHRH is a key hormone involved in the regulation of the reproductive system. The invention relates to novel peptides and peptide derivatives that can inhibit the action of natural LHRH, thereby affecting various physiological processes[4][5].
Scope of the Invention
The scope of the invention is broad and encompasses several aspects:
Pharmaceutical Compositions
The patent includes pharmaceutical compositions containing the nonapeptide and decapeptide analogs of LHRH. These compositions are designed for various therapeutic applications, including the inhibition of ovulation, prevention of ovarian hyperstimulation, and treatment of conditions such as endometriosis, prostatic hypertrophy, and precocious puberty[4][5].
Therapeutic Applications
- Inhibition of Ovulation: The compounds can be used to inhibit ovulation in female mammalian subjects, which is useful in fertility control and other reproductive health applications.
- Prevention of Ovarian Hyperstimulation: The invention prevents ovarian hyperstimulation in response to exogenous gonadotropins, a common issue in fertility treatments.
- Treatment of Endometriosis: The compounds are effective in treating endometriosis by regulating hormonal activity.
- Treatment of Prostatic Hypertrophy: The invention includes methods for treating prostatic hypertrophy in male mammalian subjects.
- Treatment of Precocious Puberty: The compounds can be used to treat precocious puberty in human subjects.
- Other Applications: Additional aspects include methods for interrupting heat in animals, terminating pregnancy in animals, and inhibiting spermatogenesis in male mammalian subjects[4][5].
Claims of the Patent
The patent includes several claims that define the scope of the invention:
Independent Claims
- Claim 1 describes a method of inhibiting ovulation in a female mammalian subject using the nonapeptide and decapeptide analogs of LHRH.
- Claim 2 outlines a method for preventing ovarian hyperstimulation in response to exogenous gonadotropins.
- Subsequent claims detail various therapeutic methods and pharmaceutical compositions containing the LHRH antagonists[5].
Dependent Claims
These claims further specify the compounds, their structures, and the methods of administration. For example, dependent claims might describe specific peptide sequences, pharmaceutical formulations, and dosages.
Patent Landscape
Prior Art and Related Patents
The patent landscape for LHRH antagonists is rich with prior art and related patents. Other patents, such as US-4628044-A, also describe LHRH antagonists and their applications, indicating a competitive and innovative field in peptide chemistry and reproductive health[2].
International Patent Offices
The global patent system, facilitated by tools like the Global Dossier and Common Citation Document (CCD), allows for the consolidation of prior art and citation data across different intellectual property offices. This helps in understanding the broader international patent landscape for similar inventions[1].
Searchable Databases
Databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO) offer comprehensive resources for searching prior art and related patents. These databases are crucial for conducting thorough patent searches and ensuring the novelty of an invention[1].
Classification and Tagging
The patent is classified under various categories, including:
- A61K38/00: Medicinal preparations containing peptides.
- Y10S930/13: Luteinizing hormone-releasing hormone; related peptides.
- Y10S930/01: Peptide or protein sequence.
These classifications help in categorizing the patent within the broader context of pharmaceutical and biotechnological inventions[4].
Legal Status
As of the current date, the legal status of the patent is listed as "Expired - Lifetime," indicating that the patent has completed its term and is no longer in force. This status is important for understanding the current intellectual property rights associated with the invention[4].
Impact and Applications
The invention described in US Patent 5,767,082 has significant implications for reproductive health and pharmaceutical research. The LHRH antagonists have been used in various clinical applications, including fertility treatments and the management of hormonal disorders.
Clinical Trials and Research
Research and clinical trials have been conducted to evaluate the efficacy and safety of these compounds. The data from these trials have contributed to the understanding of how LHRH antagonists can be used therapeutically.
Market and Commercialization
The commercialization of these compounds has led to the development of new drugs and therapies. Companies involved in pharmaceutical research have leveraged this patent to create products that address specific reproductive health needs.
Key Takeaways
- Novel Compounds: The patent introduces nonapeptide and decapeptide analogs of LHRH as antagonists.
- Therapeutic Applications: The invention includes methods for inhibiting ovulation, preventing ovarian hyperstimulation, and treating various hormonal disorders.
- Patent Claims: The patent includes detailed claims that define the scope of the invention.
- Patent Landscape: The patent is part of a broader landscape of LHRH-related inventions and global patent databases.
- Legal Status: The patent has expired, indicating that the intellectual property rights are no longer in force.
FAQs
What is the main subject of US Patent 5,767,082?
The main subject of US Patent 5,767,082 is the nonapeptide and decapeptide analogs of Luteinizing Hormone-Releasing Hormone (LHRH) and their use as LHRH antagonists.
What are the therapeutic applications of the LHRH antagonists described in the patent?
The therapeutic applications include inhibiting ovulation, preventing ovarian hyperstimulation, treating endometriosis, prostatic hypertrophy, and precocious puberty, among others.
What is the current legal status of US Patent 5,767,082?
The patent is listed as "Expired - Lifetime," indicating that it is no longer in force.
How does the Global Dossier impact the patent landscape for this invention?
The Global Dossier provides a single portal to access file histories of related applications from participating IP Offices, helping to consolidate prior art and citation data.
What databases can be used to search for related patents and prior art?
Databases such as those provided by the EPO, JPO, WIPO, and the USPTO can be used to search for related patents and prior art.
Sources
- USPTO: Search for patents - USPTO
- PubChem: LHRH antagonists - Patent US-4628044-A - PubChem
- USPTO: Patent Claims Research Dataset - USPTO
- Google Patents: US5767082A - Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
- Justia Patents: US Patent for Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
